Sun Pharmas购买检查点治疗药物,价值高达355万元,以扩大癌症药物供应。 Sun Pharma buys Checkpoint Therapeutics for up to $355M to expand cancer drug offerings.

印度制药公司Sun Pharma正以3.55亿美元购买以美国为基地的检查点治疗药物,以扩大其肿瘤组合。 Sun Pharma, an Indian pharmaceutical company, is acquiring U.S.-based Checkpoint Therapeutics for up to $355 million to expand its oncology portfolio. Checkpoint Therapeutics 获得 FDA 批准用于治疗晚期皮肤癌的 UNLOXCYT。 Checkpoint Therapeutics received FDA approval for UNLOXCYT, a treatment for advanced skin cancer. 这项交易包括预付现金,每股4.10美元,如果达到某些里程碑,每股可能增加0.70美元。 The deal includes an upfront cash payment of $4.10 per share and a potential additional $0.70 per share if certain milestones are met. 预计该购置将于2025年第二季度完成。 The acquisition is expected to complete in the second quarter of 2025.